Novartis Ag ADR (NVS)

Jan 16, 2025, 4:08 PM EST - 1 day ago

US appeals court lifts pause on generic version of Novartis' Entresto

Jan 16, 2025, 12:09 PM EST - 1 day ago

Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug

OTLK

Jan 15, 2025, 7:01 PM EST - 2 days ago

Novartis loses emergency bid to block Entresto generic in US

Jan 14, 2025, 2:57 PM EST - 3 days ago

Novartis AG (NVS) J.P. Morgan 43rd Annual Healthcare Conference (Transcript)

Jan 14, 2025, 1:00 PM EST - 3 days ago

Novartis CEO: We need to get Europe to pay its fair share

Jan 14, 2025, 10:19 AM EST - 3 days ago

Novartis CEO Vas Narasimhan: Expect solid growth this year top and bottom line

Jan 13, 2025, 6:10 PM EST - 4 days ago

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

ABBV AMGN AZN BNTX FBCG GILD GSK

Jan 13, 2025, 12:08 PM EST - 4 days ago

Novartis And BioAge Team Up To Develop Aging Therapies And Boost Investor Potential

BIOA

Jan 13, 2025, 1:15 AM EST - 4 days ago

Novartis Entresto® US patent upheld by US Court of Appeals

Jan 10, 2025, 4:32 PM EST - 7 days ago

Novartis: Explaining YE24 Loss Of Momentum, Outlining Prospects For 2025

Jan 10, 2025, 10:25 AM EST - 7 days ago

AI, vaccine distrust, & the future of healthcare: Novartis CEO

Jan 9, 2025, 9:00 AM EST - 8 days ago

Light Horse Therapeutics Enters Into Strategic Collaboration With Novartis

Dec 30, 2024, 11:01 AM EST - 18 days ago

Novartis gene therapy helps children with rare muscle disorder in study

Dec 30, 2024, 12:45 AM EST - 18 days ago

Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA

Dec 27, 2024, 11:19 AM EST - 21 days ago

Novartis must face claims it paid kickbacks to promote MS drug, US appeals court rules

Dec 19, 2024, 5:21 AM EST - 4 weeks ago

Some 330 jobs hit as Novartis closes Morphosys, WiWo reports

MOR

Dec 13, 2024, 7:28 AM EST - 5 weeks ago

Novartis: Time To Increase

Dec 10, 2024, 9:00 AM EST - 5 weeks ago

Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer

Dec 8, 2024, 12:30 PM EST - 5 weeks ago

Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML

Dec 7, 2024, 7:00 AM EST - 5 weeks ago

12 High-Yield Dividend Aristocrats To Weather The Coming 2025 Storm In Style

BDX CLX DEO FTS HRL JNJ KMB

Dec 6, 2024, 1:15 AM EST - 6 weeks ago

New Phase IIIB data shows Novartis Fabhalta® improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy

Dec 4, 2024, 12:07 PM EST - 6 weeks ago

Novartis cannot block generic of best-selling heart drug, US appeals court says

Dec 2, 2024, 4:27 PM EST - 6 weeks ago

Olema: Cash Infusion And Supply Agreement With Novartis Carries The Tide Forward

Dec 2, 2024, 12:58 PM EST - 6 weeks ago

PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program

PTCT

Dec 2, 2024, 7:14 AM EST - 6 weeks ago

PTC Therapeutics signs up to $1.9 billion licensing deal with Novartis

PTCT

Dec 2, 2024, 7:00 AM EST - 6 weeks ago

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program

PTCT

Nov 27, 2024, 1:15 AM EST - 7 weeks ago

Novartis Kisqali® receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence

Nov 25, 2024, 1:15 AM EST - 7 weeks ago

Novartis highlights new 96-week results from Phase III Scemblix® ASC4FIRST trial at ASH and late-breaking analysis from Phase III Kisqali® NATALEE trial at SABCS

Nov 21, 2024, 3:12 AM EST - 2 months ago

Novartis: launch of Morphosys drug by could be 2027 or later

MOR

Nov 21, 2024, 2:07 AM EST - 2 months ago

Novartis Lifts Sales Outlook on Key Drugs, Pipeline Portfolio

Nov 21, 2024, 1:15 AM EST - 2 months ago

Novartis raises annual sales guidance until 2028

Nov 21, 2024, 1:00 AM EST - 2 months ago

Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth

Nov 19, 2024, 8:00 AM EST - 2 months ago

Novartis ranks first in 2024 Access to Medicine Index

Nov 18, 2024, 8:00 AM EST - 2 months ago

Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate

Nov 12, 2024, 8:00 AM EST - 2 months ago

Cellares Appoints Ossama Eissa, Former Novartis, Lonza and Legend Biopharma Leader, as Chief Operating Officer

Nov 12, 2024, 7:39 AM EST - 2 months ago

Schrödinger's stock pops as it enters collaboration pact with Novartis worth up to $2.5 billion

Nov 12, 2024, 6:45 AM EST - 2 months ago

Schrödinger Announces Multi-Target Collaboration and Expanded Software Licensing Agreement with Novartis

Nov 2, 2024, 5:38 AM EDT - 2 months ago

Novartis CEO 'very confident' on sales target, doesn't fear patent cliff - newspaper

Oct 30, 2024, 3:12 PM EDT - 2 months ago

Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights

Oct 30, 2024, 7:00 AM EDT - 2 months ago

Novartis: It's Not Too Late To Buy This Dividend Stock Now

Oct 30, 2024, 4:10 AM EDT - 2 months ago

Focus remains on R&D to drive growth of blockbuster drugs, says Novartis CEO

Oct 29, 2024, 5:05 PM EDT - 2 months ago

Novartis: Strong Financials, But Market Skepticism Persists Amid Pipeline Concerns

Oct 29, 2024, 3:03 PM EDT - 2 months ago

Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile

Oct 29, 2024, 12:13 PM EDT - 2 months ago

Novartis AG (NVS) Q3 2024 Earnings Call Transcript

Oct 29, 2024, 11:00 AM EDT - 2 months ago

Novartis CEO on the impact of the U.S. election for pharma

Oct 29, 2024, 7:40 AM EDT - 2 months ago

Novartis Posts Results Above Estimates, Raises Outlook

Oct 29, 2024, 7:09 AM EDT - 2 months ago

Novartis Lifts Guidance Again After Key Drugs Help Results

Oct 29, 2024, 3:58 AM EDT - 2 months ago

Novartis hikes FY forecast after Q3 profit beat

Oct 29, 2024, 3:42 AM EDT - 2 months ago

Novartis: we are exploring obesity drugs but other areas provide growth for years

Oct 29, 2024, 2:10 AM EDT - 2 months ago

Novartis lifts 2024 guidance for 3rd time on wider use of its drugs